儿童肝母细胞瘤治疗进展

Advance in the treatment of children with hepatoblastoma

肝母细胞瘤（HB）是儿童期最常见的肝脏恶性肿瘤。手术切除曾是治疗HB的主要手段，但60％以上的患儿在确诊时已经无法完整切除肿块，即使手术完全切除，仍有30％的患儿可出现肿瘤复发。随着新辅助化疗概念的引入，HB的治疗已从单一的手术切除发展为多学科综合治疗模式，极大地改善了HB患儿的预后，但高危患者的治疗仍存在较大挑战。化疗方案的优化、手术时机的把握、按危险度分层施治以及不断寻找新的潜在治疗靶点和与预后相关的高危因素等，已成为世界上各主要儿童HB协作组关注的重点。

Hepatoblastoma （HB） is the most common malignant liver tumor in children. Surgical resection was the major treatment approach to HB,whereas more than 60% patients had unresectable mass at diagnosis,even though complete resection,there were about 30% patients recurrent. With the introduction of adjuvant chemotherapy,the treat- ment of HB has been developed to muhidisciplinary cooperation from single surgical resection, such strategy greatly im- proved the prognosis of children with HB, but there still be a great challenge in the treatment of high - risk patients. All famous children＇s HB study groups have begun to focus on the optimization of chemotherapy, surgery opportunity, strate- gy based on risk - stratification, looking for new potential therapeutic targets and prognosis - related risk factors.